OM:BIOA BBiotechs
How New Lecanemab Data Releases at CTAD 2023 Could Shape BioArctic's (OM:BIOA B) Investment Case
BioArctic's partner Eisai recently announced the upcoming presentation of extensive new lecanemab (Leqembi) clinical and real-world data at the Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego from December 1-4, covering long-term treatment outcomes, subcutaneous administration, and real-world registry findings.
These disclosures are expected to provide important insights into the long-term effectiveness, patient experience, and potential healthcare resource savings of...